MSD, Moderna start phase 3 adjuvant lung cancer trial
MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta
Newsletters and Deep Dive digital magazine
MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class t
Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 gl
11-12 November 2024 in London, UK
Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running.
Editor's Picks
Newsletters and Deep Dive
digital magazine